CTLA4 and colorectal carcinoma: Immunotherapy has shown limited efficacy in MSS CRC; however, some CRC patients with MSS were exceptional response to neoadjuvant botensilimab (BOT), an Fc-enhanced next-generation anti–CTLA4 antibody, alongside balstilimab (BAL; an anti-PD-1 antibody) [20].